cancer immunotherapy

From Aaushi
Jump to navigation Jump to search

Introduction

The 4 FDA-approved cancer immunotherapies are checkpoint inhibitors

Epidemiology

Adverse effects

Laboratory

Mechanism of action

Comparative biology

Notes

  • 2018 Nobel Prize in Physiology or Medicine 2018 awarded jointly to James P. Allison & Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation[6]

More general terms

More specific terms

Additional terms

References

  1. Young K, Sadoughi S, Sofair A Cancer Immunotherapies May Send Immune System into Overdrive. Physician's First Watch, Dec 5, 2016 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
  2. 2.0 2.1 Nelson R Cancer Vaccine Works 'Startlingly Well' in Mouse Model. Medscape - Feb 08, 2018 https://www.medscape.com/viewarticle/892447
    Sagiv-Barfi I, Czerwinski DK, Levy S Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018 Jan 31;10(426) <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29386357 <Internet> http://stm.sciencemag.org/content/10/426/eaan4488.short
  3. 3.0 3.1 3.2 Kerr DJ Overlooked Biomarker May Predict Cancer Immunotherapy Response. Medscaape. Feb 15, 2018 https://www.medscape.com/viewarticle/892475
    Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017 Jan 20;355(6322) pii: eaaf8399 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28104840 Free PMC Article
  4. 4.0 4.1 Bankhead C Drug May Reverse Anti-PD-1 Resistance in Melanoma. Responses in 22% of resistant patients with TLR9 agonist. MedPage Today. April 19, 2018 https://www.medpagetoday.com/meetingcoverage/aacr/72435
    Milhem M, et al Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. American Association for Cancer Research (AACR 2018) Abstract CT144
  5. 5.0 5.1 Harrison P. Men Do Better than Women on Cancer Immunotherapies. Overall survival improvement twice as great, meta-analysis finds. MedPage Today. May 16, 2018 https://www.medpagetoday.com/hematologyoncology/skincancer/72908
    Conforti F, Pala L, Bagnardi V et al Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 2018; PMID: https://www.ncbi.nlm.nih.gov/pubmed/29778737 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30261-4/fulltext
    Abdel-Rahman O. Does a patient's sex predict the efficacy of cancer immunotherapy? Lancet Oncol 2018; PMID: https://www.ncbi.nlm.nih.gov/pubmed/29778735 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30270-5/fulltext
  6. 6.0 6.1 Nobel Prize Press release. Oct 1, 2018 https://www.nobelprize.org/prizes/medicine/2018/press-release/
  7. Murphy WJ, Longo DL. The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy. JAMA. Published online March 18, 2019. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30882850 https://jamanetwork.com/journals/jama/fullarticle/2728948